Oral contraceptives and the risk of venous thrombosis

New England Journal of Medicine

Volumn 344, Issue 20, 2001, Pages 1527-1535

  Vandenbroucke, Jan P ^a,b   Rosing, Jan ^c   Bloemenkamp, Kitty W M ^a   Middeldorp, Saskia ^d   Helmerhorst, Frans M ^a   Bouma, Bonno N ^e   Rosendaal, Frits R ^a,b  

^a Department of Clinical Epidemiology ^*  (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; GESTAGEN; LOW DOSE ORAL CONTRACEPTIVE;

ANTICOAGULATION; ANTITHROMBIN DEFICIENCY; DISEASE PREDISPOSITION; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEREDITY; HUMAN; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; VEIN THROMBOSIS;

BLOOD COAGULATION; CONTRACEPTIVES, ORAL; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HUMANS; PROGESTINS; RISK; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0035902193     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200105173442007     Document Type: Review

References (98)

1. Coagulation effects of oral contraception
2. Cardiovascular effects of oral contraceptives: A review
3. Effect of oral contraceptives on haemostasis variables
4. Blood coagulation and oral contraceptives: A critical review
5. Oral contraceptive use and myocardial infarction
6. Cardiovascular disease and combined oral contraceptives: Reviewing the evidence and balancing the risks
7. The natural history and epidemiology of venous thrombosis
8. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
9. Oral contraceptives and cardiovascular disease
10. Cardiovascular disease and steroid hormone contraception: Report of a WHO scientific group
11. Using epidemiological data to guide clinical practice: Review of studies on cardiovascular disease and use of combined oral contraceptives
12. Venous thromboembolism in relation to oral contraceptive use
13. Oral contraceptives and venous thromboembolism: Findings in a large prospective study
14. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study
15. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
16. The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational research
17. Investigation of relation between use of oral contraceptives and thromboembolic disease
18. Thrombosis with low-estrogen oral contraceptives
19. Oral contraceptives and venous thromboembolism: A case-control study designed to minimize detection bias
20. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias
21. Effect of different progestogens in low dose oestrogen oral contraceptives on venous thromboembolic disease
22. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
23. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study
24. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
25. Oral contraception was not associated with venous thromboembolic disease in recent study
26. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis
27. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism
28. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism
29. Oral contraceptives and venous thromboembolism: A case-control study
30. The risk of venous thromboembolism in users of postcoital contraceptive pills
31. Venous thromboembolism among new users of different oral contraceptives
32. Risk of idiopathic venous thromboembolism in users of progestagens alone
33. The use of a large-scale surveillance system in Planned Parenthood Federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives
34. Oral contraceptives and fatal pulmonary embolism
35. Safety of combined oral contraceptive pills
36. Third-generation oral contraceptive and deep venous thrombosis: From epidemiologic controversy to new insight in coagulation
37. Therapeutic controversy: The safety of third-generation oral contraceptives
38. Risk of fatal pulmonary embolism with oral contraceptives
39. Third generation oral contraceptives
40. Bias versus causality: Interpreting recent evidence of oral contraceptive studies
41. The differential risk of oral contraceptives: The impact of full exposure history
42. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism
43. Third-generation oral contraceptives: How risky?
44. Third generation oral contraception and venous thromboembolism
45. Newer oral contraceptives and the risk of venous thromboembolism
46. The third generation oral contraceptive controversy: The evidence shows they are less safe than second generation pills
47. Combined oral contraceptives containing desogestrel or gestodene and the risk of venous thromboembolism
48. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
49. Mutation in blood coagulation factor V associated with resistance to activated protein C
50. World distribution of factor V Leiden
51. Ethnic distribution of factor V Leiden in 4047 men and women: Implications for venous thromboembolism screening
52. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
53. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives
54. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis
55. Protein C deficiency in a controlled series of unselected outpatients: An infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study)
56. The risk of thromboembolism in asymptomatic patients with prorein C and protein S deficiency: A prospective cohort study
57. Incidence of venous thromboembolism in families with inherited thrombophilia
58. The role of drugs, particularly oral contraceptives, in triggering thrombosis in congenital defects of coagulation inhibitors: A study of six patients
59. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
60. Geographic distribution of the 20210 G to A prothrombin variant
61. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects
62. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis
63. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism
64. Venous thromboembolic disease and ABO blood type: A cooperative study
65. Venous thrombosis, oral contraceptives and high factor VIII levels
66. ABO blood group and risk of venous thrombosis in heterozygous carriers of factor V Leiden
67. Factor XI and protection of the fibrin clot against lysis - A role for the intrinsic pathway of coagulation in fibrinolysis
68. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: A cross-over study
69. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa
70. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: Influence of the factor VK506Q mutation
71. Resistance to activated protein C is reduced in women using oral contraceptives
72. Resistance to activated protein C in healthy women taking oral contraceptives
73. Sensitivity to activated protein C: Influence of oral contraceptives and sex
74. Activated protein C resistance and the FV:R506Q mutation in a random population sample - Associations with cardiovascular risk factors and coagulation variables
75. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives
76. End of line for "third-generation-pill" controversy?
77. Low-dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study
78. Molecular biology and pathophysiology of APC resistance: Current insights and clinical implications
79. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
80. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism
81. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways
82. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: A randomized cross-over study of two low-dose oral contraceptives
83. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
84. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis
85. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
86. Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives
87. Hormonal contraception and risk of cardiovascular disease: An international perspective
88. Case-control study of oral contraceptives and risk of thromboembolic stroke: Results from International Study on Oral Contraceptives and Health of Young Women
89. Oral contraceptives and myocardial infarction: Results of the MICA case-control study
90. Recurrence of venous thromboembolic disease and use of oral contraceptives
91. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: Results of an international, multicenter, case-control study
92. Thrombosis, phlebitis and varicose veins
93. Factor V Leiden: Should we screen oral contraceptive users and pregnant women?
94. The long-term clinical course of acute deep venous thrombosis
95. Gesundheitsökonomische evaluation des screenings auf APC-resistenz (mutation leiden) bei neuanwenderinnen von ovulationshemmern
96. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients